def14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o |
|
Preliminary Proxy Statement |
|
o |
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
þ |
|
Definitive Proxy Statement |
|
o |
|
Definitive Additional Materials |
|
o |
|
Soliciting Material Pursuant to §240.14a-12 |
Synergetics USA, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ |
|
No fee required. |
|
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was
determined): |
|
|
|
|
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
(5) |
|
Total fee paid: |
|
|
|
|
|
o |
|
Fee paid previously with preliminary materials. |
|
o |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and
identify the filing for which the offsetting fee was paid previously. Identify the previous filing
by registration statement number, or the Form or Schedule and the date of its filing. |
|
(1) |
|
Amount Previously Paid: |
|
|
|
|
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
(3) |
|
Filing Party: |
|
|
|
|
|
|
|
(4) |
|
Date Filed: |
|
|
|
|
|
|
|
|
Persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB control number. |
SYNERGETICS
USA, INC.
3845 Corporate Centre Drive
OFallon, Missouri 63368
November 12, 2010
Dear Stockholder:
You are cordially invited to attend our Companys 2010
Annual Meeting of Stockholders, which will be held on
December 16, 2010, at 6:00 p.m., Central Time, at The
Doubletree Hotel and Conference Center located at
16625 Swingley Ridge Road, Chesterfield, Missouri 63017.
The formal Notice of Annual Meeting of Stockholders and Proxy
Statement accompanying this letter describe the business to be
acted upon at the meeting.
Your vote is important to us and your shares should be
represented at the meeting whether or not you are personally
able to attend. Accordingly, I encourage you to mark, sign, date
and return the accompanying proxy promptly.
On behalf of the Board of Directors, thank you for your
continued support of Synergetics USA, Inc.
Sincerely,
David M. Hable
President and Chief Executive Officer
SYNERGETICS
USA, INC.
NOTICE OF ANNUAL MEETING OF
STOCKHOLDERS
To Be Held on December 16,
2010
NOTICE IS HEREBY GIVEN that the 2010 Annual Meeting of
Stockholders of Synergetics USA, Inc., a Delaware corporation
(the Company), will be held on December 16,
2010, at 6:00 p.m., Central Time, at The Doubletree Hotel
and Conference Center located at 16625 Swingley Ridge Road,
Chesterfield, Missouri 63017 to act upon the following matters,
which are described more fully in the accompanying Proxy
Statement:
1. The election of two directors nominated by the
Companys Nominating and Governance Committee to serve
three year terms following approval by the stockholders at the
Annual Meeting;
2. The ratification of the appointment of UHY LLP
(UHY) as the Companys independent registered
public accounting firm for fiscal 2011; and
3. Such other business as may properly come before the
meeting
and/or any
adjournment thereof.
All holders of common stock of record at the close of business
on November 5, 2010 are entitled to notice of, and to vote
at, the Annual Meeting or any adjournment thereof.
The Board of Directors of the Company has authorized the
solicitation of proxies. Unless otherwise directed, the proxies
will be voted FOR the election of the nominees listed in the
attached Proxy Statement to be members of the Board of Directors
of the Company, FOR ratification of UHYs appointment and
on other business that may properly come before the Annual
Meeting, as the named proxies in their best judgment shall
decide.
If you submit a proxy, you may revoke such proxy at any time
prior to its exercise by notifying the Secretary of the Company
in writing at 3845 Corporate Centre Drive, OFallon,
Missouri 63368 prior to the Annual Meeting, and, if you attend
the Annual Meeting, you may revoke your proxy if previously
submitted and vote in person by notifying the Secretary of the
Company at the Annual Meeting.
Your vote is very important. Whether or not you plan to attend
the Annual Meeting, we encourage you to read the Proxy Statement
and submit your proxy as soon as possible. You may submit your
proxy for the Annual Meeting by completing, signing, dating and
returning your proxy in the pre-addressed envelope provided.
By Order of the Board of Directors,
PAMELA G. BOONE,
Secretary
OFallon, Missouri
November 12, 2010
SYNERGETICS
USA, INC.
PROXY STATEMENT
FOR THE
2010 ANNUAL MEETING OF STOCKHOLDERS
Important
Notice Regarding the Availability of Proxy Materials for the
Annual Stockholders
Meeting
To Be Held on December 16, 2010
The proxy statement and annual report to stockholders for the
fiscal year ended July 31, 2010 are available at
http://www.amstock.com/ProxyServices/ViewMaterial.asp?CoNumber=06536.
GENERAL
INFORMATION
This Proxy Statement is being furnished in connection with the
solicitation of proxies by the Board of Directors of Synergetics
USA, Inc., a Delaware corporation (the Company),
3845 Corporate Centre Drive, OFallon, Missouri 63368, for
use at the 2010 Annual Meeting of Stockholders to be held on
December 16, 2010, at 6:00 p.m. Central Time at The
Doubletree Hotel and Conference Center located at 16625 Swingley
Ridge Road, Chesterfield, Missouri 63017. The Board of Directors
of the Company urges you to promptly execute and return your
proxy in the enclosed envelope, even if you plan to attend the
Annual Meeting. This is designed to authenticate
stockholders identities, to allow stockholders to give
their voting instructions and to confirm that stockholders
instructions have been recorded properly. This Proxy Statement
and the enclosed proxy card are being mailed to the stockholders
of the Company on or about November 12, 2010.
Any stockholder submitting a proxy may revoke such proxy at any
time prior to its exercise by notifying the Secretary of the
Company, in writing, prior to the Annual Meeting. Any
stockholder attending the Annual Meeting may revoke his or her
proxy and vote personally by notifying the Secretary of the
Company at the Annual Meeting. For additional information on how
to obtain directions to be able to attend the Annual Meeting and
vote in person, please write to the Companys Secretary at
Synergetics USA, Inc., 3845 Corporate Centre Drive,
OFallon, Missouri 63368 or call
(636) 939-5100.
Only stockholders of record at the close of business on
November 5, 2010 (the Record Date), will be
entitled to notice of, and to vote at, the Annual Meeting or any
adjournment thereof. At the close of business on the Record
Date, the Company had 24,840,441 outstanding shares of common
stock, $0.001 par value per share (the Common
Stock). Each share of Common Stock entitles the holder
thereof to one vote for each share of Common Stock held of
record on the Record Date on each matter that may properly come
before the Annual Meeting. If you are a beneficial holder and do
not provide specific voting instructions to your broker, under a
recent rule change, the organization that holds your shares will
not be authorized to vote on the election of directors.
Accordingly, we encourage you to vote promptly, even if you plan
to attend the Annual Meeting.
If the accompanying proxy card is signed and returned, the
shares represented thereby will be voted in accordance with the
directions on the proxy card. Unless a stockholder specifies
otherwise therein, the proxy will be voted in accordance with
the recommendations of the Board of Directors on all proposals.
The presence in person or by proxy of a majority of the voting
power represented by outstanding shares of Common Stock will
constitute a quorum for the transaction of business at the
Annual Meeting.
Directors will be elected by a plurality of the voting power
represented and entitled to vote at the Annual Meeting. The
passage of any other proposal will be determined by the
affirmative vote of the majority of the voting power represented
and entitled to vote at the Annual Meeting. In the election of
directors, abstentions and broker non-votes will not affect the
outcome except in determining the presence of a quorum; they
will not be counted toward the number of votes required for any
nominees election. An instruction to abstain
from voting on any other proposal will have the same effect as a
vote against the proposal. Broker non-votes will not be
considered as present and entitled to vote on the proposals.
Therefore, broker non-votes will have no effect on the number of
affirmative votes required to adopt such proposal.
PROPOSAL 1
ELECTION OF DIRECTORS
The Companys Amended and Restated Bylaws provide that the
Board shall consist of not less than five nor more than 11
members, the exact number of which shall be determined by the
Board. The number of directors on the Companys Board of
Directors is currently set at seven directors, divided into
three classes, with each class serving three-year staggered
terms. The Board is comprised of four directors who satisfy the
definition of an independent director set forth in the listing
standards of the Nasdaq Stock Market Inc. (Nasdaq)
and the Companys Corporate Governance
Guidelines Ms. Hinshaw, Mr. Cardinale,
Mr. Guarch and Mr. Dick each, an Independent
Director and collectively the Independent Directors and
three senior management persons Mr. Hable,
Mr. Gampp and Dr. Malis, each a Management
Director and collectively the Management
Directors.
The terms of Lawrence C. Cardinale and Guy R. Guarch expire at
the 2010 Annual Meeting. Messrs. Cardinale and Guarch have
been nominated by the Nominating and Governance Committee for
re-election. The Board of Directors of the Company recommends a
vote FOR the two nominees. If re-elected, each nominee will
serve until the annual election of directors in the year 2013 or
until his successor is duly elected and qualified, or his
earlier death, resignation or removal. If any nominee is
unavailable for election, an event which the Board of Directors
of the Company does not presently anticipate, the persons named
in the enclosed proxy intend to vote the proxies solicited
hereby FOR the election of such other nominee or nominees as may
be nominated by the Board of Directors. For information
regarding revocation of a proxy, see General
Information on Page 1.
Based on the recommendation of the Nominating and Corporate
Governance Committee, both of the nominees have been approved
unanimously by the Board of Directors of the Company for
re-election. Below is biographical and other information about
each nominee for election as a director and each current
director whose term continues after the Annual Meeting.
Following each nominees or directors biographical
information is information concerning the particular experience,
qualifications, attributes
and/or
skills that led the Nominating and Governance Committee and the
Board to determine that each nominee should serve as a director,
or each director should continue to serve as a director, as the
case may be.
Nominees
for Directors to be Re-Elected at the 2010 Annual Meeting for
Terms expiring in 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
|
|
|
|
|
|
|
of Term (if
|
Name
|
|
Age
|
|
|
Biography
|
|
Re-Elected)
|
|
|
|
|
|
|
|
|
|
|
Lawrence C. Cardinale
|
|
|
72
|
|
|
Lawrence C. Cardinale has served as a director of the Company
since 2005. From July 31, 2008 until January 28, 2009, Mr.
Cardinale, along with the Companys other Independent
Directors, served as the Companys principal executive
officer, generally on a weekly rotating basis.
Mr. Cardinale received his B.S.B.A. in Business from
Washington University in St. Louis, Missouri and is retired
after working in the medical industry since 1966. During his
over 35 years working in the field of medical
manufacturing, he held various management positions, including
Plant Manager, Director of Manufacturing, Director of Corporate
Engineering, Director of Operations Planning, Vice President of
Manufacturing-International and Vice President-Global
Manufacturing and Engineering of a multi-national medical
manufacturing company. Mr. Cardinale also owned and operated a
scientific laboratory instrument business concentrating in the
life sciences field, which manufactured and marketed tissue
sectioning, microforge and micromanipulation instruments and
pipeting devices. Mr. Cardinale formerly served as a board
member of Coretech-Holdings LLC, a St. Louis-based life
sciences and medical device manufacturing company, and McCormick
Scientific, LLC.
|
|
2013
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
|
|
|
|
|
|
|
of Term (if
|
Name
|
|
Age
|
|
|
Biography
|
|
Re-Elected)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mr. Cardinales extensive experience in the medical
manufacturing industry enables him to bring valuable insight
regarding the industry to the Board. In addition,
Mr. Cardinales service in senior management positions
provides the Board with significant senior leadership experience.
|
|
|
|
|
|
|
|
|
|
|
|
Guy R. Guarch
|
|
|
70
|
|
|
Guy R. Guarch has been a director of the Company since 2005,
when Synergetics, Inc. merged with Valley Forge Scientific Corp.
(Valley Forge) (now known as Synergetics USA, Inc.
or the Company). From July 31, 2008 until January
28, 2009, Mr. Guarch, along with the Companys other
Independent Directors, served as the Companys principal
executive officer, generally on a weekly rotating basis.
Mr. Guarch retired in 2001 from C.R. Bard, Inc. where he
spent 32 years in various sales, marketing and management
roles. Bard is a leading developer, manufacturer and marketer of
health care products used for vascular, urological and oncologic
diagnosis and intervention. From 1993 to 2001, Mr. Guarch
served as Regional Vice President Corporate Account Manager for
Bards Southeast Region. He worked as President of Bard
Venture Division in Boston, Massachusetts from 1991 to 1993.
From 1988 to 1991, Mr. Guarch worked in London, England, as Vice
President of Sales for the Bard European Division and Managing
Director of Bard LTD, UK. Before 1988, Mr. Guarch worked in
several sales and marketing roles for Bards USCI
International Division in Boston, Massachusetts, which focused
on the design, manufacture and sale of cardiac catheters,
urological catheters and artificial arteries. Mr. Guarch
currently serves as a board member and chairman of the
governance committee for
Span-America
Medical Systems, Inc., which designs and manufactures wound
management products and which has securities registered pursuant
to Section 12 of the Securities and Exchange Act of 1934 (the
Exchange Act).
|
|
2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mr. Guarch brings senior leadership, strategic and business
development expertise to the Board from his prior positions with
C.R. Bard, Inc. In addition, he adds significant industry
experience to the Board.
|
|
|
3
Directors
whose Terms Continue beyond the 2010 Annual Meeting
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
Name
|
|
Age
|
|
Biography
|
|
of Term
|
|
|
|
|
|
|
|
|
David M. Hable
|
|
55
|
|
David M. Hable joined the Company as its President, CEO and
director in January 2009. Prior to joining the Company, Mr.
Hable served as President and CEO of Afferent Corporation, a
venture capital backed medical device company focused on neuro
stimulation therapies. Previously, he was Chairman of the Board
of ONI Medical Systems, Inc., a developer and marketer of
magnetic resonance imaging equipment for extremity applications
in non-hospital settings. Mr. Hable also spent over
20 years with Johnson & Johnson working in business
units that developed and marketed a wide range of diagnostic and
therapeutic products for the treatment of central nervous system
disorders. From 1998 to 2003, Mr. Hable served as Codman &
Shurtleffs Worldwide President, leading all functions in
the company, both domestically and internationally. Mr. Hable
has overall responsibility for the management of the Company.
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
Mr. Hable brings significant industry experience to the Board,
through his positions with Johnson & Johnson and Afferent
Corporation. In addition, Mr. Hables service in senior
management positions provides the Board with experience and
perspective in analyzing, shaping and overseeing the execution
of important operational and policy issues at a senior level.
|
|
|
|
|
|
|
|
|
|
Kurt W. Gampp, Jr.
|
|
50
|
|
Kurt W. Gampp, Jr. is the Companys Executive Vice
President and Chief Operating Officer and has served in these
positions and as a director since 2005 when Synergetics, Inc.
merged with Valley Forge. Immediately prior to the merger with
Valley Forge, Mr. Gampp served as the Executive Vice President
and Chief Operating Officer of Synergetics, Inc. and had served
in this position since Synergetics, Inc. was founded in 1991.
Mr. Gampp coordinates and supervises the manufacturing of the
Companys products and is in charge of the daily production
operations of the Company.
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
Because of his 19 years of senior management experience
with the Company, Mr. Gampp brings the Board an intimate
knowledge of the Companys day-to-day operations, business
and competitive environment and the Companys
opportunities, challenges and risks. In addition, his extensive
experience in medical manufacturing enables him to bring
valuable insight into the industry to the Board.
|
|
|
|
|
|
|
|
|
|
Jerry L. Malis
|
|
78
|
|
Jerry L. Malis is the Companys Executive Vice President
and Chief Scientific Officer and has served in these positions
and as a director since 2005. Immediately prior to the
consummation of the merger with Valley Forge, Dr. Malis
served as Valley Forges Chief Executive Officer, President
and Chairman of the Board of Valley Forge. He has published over
50 articles in the biological science, electronics and
engineering fields, and has been issued ten United States
patents. Dr. Malis coordinates and supervises the
scientific developments of the Company.
|
|
2011
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
Name
|
|
Age
|
|
Biography
|
|
of Term
|
|
|
|
|
|
|
|
|
|
|
|
|
Because of his extensive senior management experience with the
Company and Valley Forge and neurosurgical operating experience,
Dr. Malis brings the Board an intimate knowledge of the
Companys day-to-day operations, business and competitive
environment and the Companys opportunities, challenges and
risks. In addition, his extensive experience in the medical
manufacturing industry enables him to bring valuable insight
regarding the industry to the Board.
|
|
|
|
|
|
|
|
|
|
Robert H. Dick
|
|
67
|
|
Robert H. Dick has been a director of the Company since 2005,
when Synergetics, Inc. merged with Valley Forge and currently
serves as the Chairman of the Board of Directors. He has served
as Chairman of the Board of Directors since July 31, 2008. From
July 31, 2008 until January 28, 2009, Mr. Dick, along with the
Companys other Independent Directors, served as the
Companys principal executive officer, generally on a
weekly rotating basis. Prior to the merger, Mr. Dick had been a
director of Valley Forge since 1997. Mr. Dick has served as
President of R.H. Dick & Company since January 1998, a
consulting firm based in Camp Verde, Texas. From 1996 to 1998,
he was a partner with Boles, Knop & Company, Inc., an
investment banking firm in Middleburg, Virginia. From 1994 to
1996, Mr. Dick served as interim President, Chief Executive
Officer and Chief Financial Officer of two of Boles
clients. From 1982 until 1994, he served in various executive
roles with Codman & Shurtleff, Inc., a subsidiary of
Johnson & Johnson and a manufacturer of surgical
instruments, implants, equipment and other surgical products.
From 1978 to 1982, Mr. Dick was President and Chief Executive
Officer of Applied Fiberoptics, Inc., a company designing,
manufacturing and marketing fiberoptic products for medical and
defense applications, and surgical microscopes for microsurgery.
From 1969 to 1978, Mr. Dick held various sales, marketing and
general management positions with the USCI division of C.R.
Bard, Inc. Mr. Dick also serves as a member of the board,
chairman of the audit committee and member of the executive and
governance committees for Span-America Medical Systems, Inc.,
which designs and manufactures wound management products and
which has securities registered pursuant to Section 12 of the
Exchange Act.
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
Mr. Dicks extensive experience in the medical
manufacturing industry enables him to bring valuable insight
regarding the industry to the Board. He also brings financial
expertise to the Board. Mr. Dicks knowledge of financial
markets, financing and funding operations and accounting and
financial reporting processes helps the Companys directors
in understanding, advising and overseeing the Companys
capital structure, financing and investing activities, financial
reporting and internal control of such activities.
|
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
Name
|
|
Age
|
|
Biography
|
|
of Term
|
|
|
|
|
|
|
|
|
Juanita H. Hinshaw
|
|
65
|
|
Juanita H. Hinshaw has served as a director of the Company since
2005 when Synergetics, Inc. merged with Valley Forge. From July
31, 2008 until January 28, 2009, Ms. Hinshaw, along with the
Companys other Independent Directors, served as the
Companys principal executive officer, generally on a
weekly rotating basis. Ms. Hinshaw has been President and Chief
Executive Officer of H&H Advisors (a financial advisory
company) since 2005. In addition, Ms. Hinshaw served as Senior
Vice President and Chief Financial Officer of Graybar Electric
Company from May 2000 to May 2005. Graybar Electric Company
specializes in supply chain management services and distributes
high-quality components, equipment and materials for the
electrical and telecommunications industries. Ms. Hinshaw has
served as a director, chairman of the finance committee and as a
member of the audit committee for The Williams Companies, Inc.
since 2004 and has served as a director on the board, chairman
of the compensation committee and as a member of the audit
committee for Insituform Technologies, Inc. since 1999. The
Williams Company and Insituform Technologies, Inc. have
securities registered pursuant to Section 12 of the Exchange Act.
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
Ms. Hinshaw brings significant business, leadership and
management insights into many aspects of the Companys
business. She also brings financial expertise to the Board.
Ms. Hinshaws knowledge of financial markets,
financing and funding operations and accounting and financial
reporting processes helps the Companys directors in
understanding, advising and overseeing the Companys
capital structure, financing and investing activities, financial
reporting and internal control of such activities.
|
|
|
CORPORATE
GOVERNANCE
The Board recognizes that one of its key responsibilities is to
evaluate and determine its optimal leadership structure and the
Independent Directors ensure such structure provides independent
oversight of management. The Board also recognizes no single
leadership structure is right for all companies at all times.
Accordingly, the Board periodically reviews its leadership
structure as necessary to accomplish its management oversight
responsibilities.
On behalf of the stockholders, the Board oversees and guides the
Companys management and its business affairs. Board
committees, staffed by Independent Directors, assist the Board
in discharging its responsibilities. The Independent Directors
recommend the Audit Committee, Compensation Committee and
Nominating and Corporate Governance Committee structures to the
Board for ratification. In its oversight of the Company, the
Board sets the tone for the ethical standards and performance of
management, staff and the Company as a whole. The Independent
Directors constituting the Nominating and Corporate Governance
Committee recommended to the Board, and the Board has adopted
Corporate Governance Guidelines and best corporate practices
that guide the practices of the Company. The Corporate
Governance Guidelines are available on the Companys
website at www.synergeticsusa.com.
Consistent with the Companys Bylaws and Corporate
Governance Guidelines, the roles of Chairman of the Board and
CEO may be separated. The Board determined on July 31, 2008
that it was appropriate to separate the roles of Chairman and
CEO in recognition of the differences between the two roles, and
to better serve the interests of the stockholders. The CEO, in
conjunction with senior management, is responsible for
developing and recommending to the Board the strategic direction
for the Company, and for the
day-to-day
leadership of the Company, and he is responsible, together with
senior management, for the overall performance of the Company,
6
with such performance measurement based on operating and
strategic plans ratified at various times by the Board. The
duties of the Chairman include, but are not limited to:
|
|
|
|
|
Presiding over all meetings of the Board,
|
|
|
|
Preparing the agenda for Board meetings in consultation with
other Independent Directors, the CEO and other Management
Directors and members of senior management,
|
|
|
|
Providing the CEO ongoing direction regarding Independent
Director, Board Committee and Board needs, interests, opinions
and decisions,
|
|
|
|
Calling and presiding over meetings of the Independent Directors,
|
|
|
|
Serving on any Special Committees as may be appointed by the
Nominating and Corporate Governance Committee,
|
|
|
|
Managing the Boards process for annual evaluation of the
CEO, and
|
|
|
|
Such other activities as may from
time-to-time
be determined by the Board to be in the best interests of the
stockholders.
|
In carrying out his responsibilities, the Chairman preserves the
distinction between management and Board oversight by
maintaining managements responsibility for:
(i) developing and frequently updating corporate strategy,
and recommending such strategy to the Board for critique and
ratification, (ii) taking such actions as necessary to
minimize risks to the Company and the stockholders and
(iii) the overall performance of the Company, with such
performance measurement based on operating and strategic plans
ratified at various times by the Board.
The Board believes that there are advantages to the separate
Chairman and CEO positions, including:
|
|
|
|
|
Enhanced communications and relations between the Board, the CEO
and other members of senior management,
|
|
|
|
Assisting the Board in reaching consensus on particular
strategies and policies, and
|
|
|
|
Facilitating robust director, Board and CEO evaluation processes.
|
The Companys Corporate Governance Guidelines provide that
Independent Directors should meet privately in executive session
after each Board meeting, after each Board committee meeting and
otherwise as needed. During fiscal 2010, the Independent
Directors held four meetings in conjunction with regularly
scheduled Board meetings and 37 special meetings for a total of
41 times. Each of our directors attended at least 75% of all the
meetings of the Board and those committees on which he or she
served during fiscal year 2010, either in person or
telephonically. The Board of Directors encourages all members to
attend stockholder meetings, but has not adopted a formal policy
regarding attendance. All of the Companys directors, with
the exception of Dr. Malis, attended last years
annual stockholders meeting.
Risk
Management Oversight
The Board is actively involved in the oversight of risks that
could affect the Company. This oversight is conducted primarily
through committees of the Board, but the full Board has retained
responsibility for general oversight of risks. The Audit
Committee oversees management of financial and information
technology risks. The Compensation Committee is responsible for
overseeing the management of risks relating to the
Companys executive compensation plans and arrangements.
The Nominating and Corporate Governance Committee manages risks
associated with the independence of the Board and potential
conflicts of interest. The Board satisfies its responsibility
for general oversight of risks through reports by each committee
chair regarding the committees considerations and actions,
as well as minutes from the meetings and through regular reports
directly from officers responsible for oversight of particular
risks within the Company.
7
Director
Independence
The Board of Directors has determined that each of
Ms. Hinshaw, Mr. Cardinale, Mr. Guarch and
Mr. Dick is an Independent Director. In addition, the Board
of Directors has determined that each of the members of the
Audit Committee satisfies the additional conditions for
independence for Audit Committee members required by Nasdaq.
Board
Committees
The Board of Directors maintains the following three standing
committees: an Audit Committee, a Compensation Committee, a
Nominating and Corporate Governance Committee, and from time to
time, the Nominating and Corporate Governance Committee may
appoint a Special Committee of Independent Directors to deal
with such matters as described in the charter. Each of these
committees operates pursuant to a written charter setting forth
the functions and responsibilities of the committee, which may
be reviewed on our website at www.synergeticsusa.com and
are also available to stockholders in print upon request.
Audit
Committee
The Audit Committee is composed entirely of Independent
Directors and is responsible for the appointment, evaluation,
compensation and oversight of the work of the independent
registered public accounting firm and, where appropriate, the
dismissal of the independent registered public accounting firm.
Furthermore, the Audit Committee is responsible for meeting with
the independent registered public accounting firm and other
corporate officers to review matters relating to financial
reporting and accounting procedures and policies. Among other
responsibilities, the Audit Committee also reviews financial
information provided to stockholders and others, assesses the
adequacy of financial, accounting, operating and disclosure
controls, evaluates the scope of the audits of the independent
registered public accounting firm and internal auditors, and
reports on the results of such audits to the Board of Directors.
The current members of the Audit Committee are Ms. Hinshaw
(Chairperson), Mr. Dick, and Mr. Cardinale, all of
whom meet all applicable standards for Audit Committee
membership under the Nasdaq listing standards and Securities and
Exchange Commission (SEC) rules. The Audit Committee
held four meetings during the last fiscal year.
Compensation
Committee
The Compensation Committee is composed entirely of Independent
Directors and is responsible for administering the
Companys compensation programs and recommending to the
Board of Directors other compensation and benefits of the Chief
Executive Officer and all named executive officers. The current
members of the Compensation Committee are Mr. Dick
(Chairperson), Mr. Cardinale and Mr. Guarch. The
Compensation Committee held four meetings during the last fiscal
year.
The Compensation Committee meets after the end of each fiscal
year to determine and recommend to the Board for approval the
compensation packages for executive officers in light of the
Companys compensation philosophy and objectives. The
Compensation Committee considers recommendations from the Chief
Executive Officer as to compensation for each executive officer
based upon their performance against Company and personal
objectives, other than himself. The Compensation Committee has
full responsibility to recommend to the Independent Directors of
the Board the compensation package of the Chief Executive
Officer and the named executive officers. The Compensation
Committee may not delegate its authority regarding executive
compensation.
During the fiscal year ended July 31, 2010, the Company
engaged Mercer, a compensation consultant, to aid management and
the Compensation Committee in its review of key compensation
program components and total compensation paid to individuals in
positions similarly situated to those of our executives,
including similar positions at our peer group companies.
Management provided the Compensation Committee with the
information received from the compensation consultant. The data
the Company reviewed included base salary, annual bonus or
incentive cash payments and long-term incentive components of
pay or certain survey market data where peer data for a like
position was not available. The Compensation Committee has taken
the compensation consultants recommendations into
consideration in the enhancement of the annual objectives based
incentive cash payments and the rate at which executives can
accumulate stock options under the long-term incentive program,
both of which improvements will be implemented for fiscal year
2011 compensation.
8
Nominating
and Corporate Governance Committee
The members of the Companys Nominating and Corporate
Governance Committee are Mr. Cardinale (Chairperson),
Mr. Dick and Mr. Guarch, all of whom are Independent
Directors. The Nominating and Corporate Governance Committee is
responsible for identifying individuals qualified to become
members of the Board of Directors, recommending to the Board of
Directors the director nominees to be proposed for election by
the stockholders and recommending to the Board of Directors
corporate governance guidelines and procedures applicable to the
Company. The Nominating and Corporate Governance Committee held
five meetings during the last fiscal year.
From time to time, the Nominating and Corporate Governance
Committee may appoint a Special Committee of Independent
Directors to deal with such matters as described in the charter.
The Nominating and Corporate Governance Committee will consider
director nominees recommended by stockholders of the Company.
Each stockholder must comply with applicable requirements of the
Companys Amended and Restated Bylaws and the Exchange Act
with respect to the nomination of, or proposal of, nominees for
election as directors of the Company. Stockholders should submit
any such nominations, together with appropriate biographical
information and a description of the nominees
qualifications to serve as director, to the Chairperson of the
Nominating and Corporate Governance Committee,
c/o Pamela
G. Boone, Secretary, Synergetics USA, Inc., 3845 Corporate
Centre Drive, OFallon, Missouri 63368. The Companys
Corporate Governance Guidelines do not require that qualified
director candidates should be limited by specific selection
criteria. Candidates are selected for, among other things, their
independence, integrity, diverse experience, leadership ability,
ability to exercise sound judgment, scientific expertise,
experience at policy-making levels involving issues affecting
business, government, education and technology, and experience
relevant to the Companys global medical device
microsurgery business. While there is no formal policy with
respect to diversity, the Nominating and Corporate Governance
Committee does consider such issues as diversity of education,
professional experience, differences of viewpoints and skills
when assessing individual director nominees. Final approval of a
candidate is determined by the full Board of Directors. Nominees
to be evaluated by the Nominating and Corporate Governance
Committee for future vacancies on the Board of Directors will be
selected by the Nominating and Corporate Governance Committee
from candidates recommended by multiple sources, including
members of the Board of Directors, senior management,
independent search firms, stockholders and other sources, all of
whom will be evaluated based on the same criteria.
Code of
Business Conduct and Ethics
The Company has established a Code of Business Conduct and
Ethics, which is applicable to all of its employees, officers
and directors. The Code is available on the Companys
website at www.synergeticsusa.com and also available to
stockholders in print upon request. We intend to post any future
amendments and revisions to the Code of Business Conduct and
Ethics on our website.
COMMUNICATIONS
WITH THE BOARD OF DIRECTORS
Stockholders may communicate directly with the Board of
Directors, as a group, or any individual director by submitting
written correspondence addressed to the Board or an individual
director at Synergetics USA, Inc., 3845 Corporate Centre
Drive, OFallon, Missouri 63368. All communications are
relayed to the appropriate Board member or members.
DIRECTOR
COMPENSATION
Directors who are neither employees of the Company nor an
immediate family member of an officer of the Company are paid
$750 for each meeting of the Board of Directors and each meeting
of a committee of the Board of Directors that they attend. The
Chairperson of the Audit Committee receives $2,250 for each
meeting of the Audit Committee that he or she attends. All
directors are entitled to reimbursement for travel and lodging
expenses incurred in connection with their attendance at
meetings. In addition, the Independent Directors receive
compensation at the standard Board meeting rate of $750 per day
for each day spent at the Company and each day spent
9
away from personal business on Company business. In addition,
the Independent Directors receive $500 per meeting for each
telephonic meeting of the Independent Directors or on Company
business. As of October 1, 2010, these rates were increased
from $750 per meeting to $950 per meeting and from $500 per
telephonic meeting to $650 per telephonic meeting for
Mr. Cardinale, Mr. Guarch and Ms. Hinshaw. This
compensation arrangement has been approved by the Management
Directors and the Chairman. Directors who are also employees of
the Company do not receive compensation for their services as
members of the Board of Directors.
Compensation for members of the Board has been established and
will be reviewed annually by the Compensation Committee. The
Compensation Committee may not delegate its authority regarding
director compensation, and, except as described above, no
executive officer plays a role in determining the amount of
director compensation. The Compensation Committee considers the
amount of time directors dedicate to Company matters and the
need to attract and retain qualified directors when determining
Board compensation. For example, the Compensation Committee has
approved additional compensation for the Audit Committee
Chairperson in recognition of the time commitment required by
such position.
To align the interests of directors with those of the
Companys stockholders, each Independent Director also
receives an option to purchase 10,000 shares of the
Companys Common Stock each year in which he or she is
elected, appointed, or re-elected to serve as a director
pursuant to the Amended and Restated 2005 Non-Employee
Directors Stock Option Plan.
The following table discloses compensation paid for the fiscal
year ended July 31, 2010 to the directors for serving as
members of the Board. Directors who are also employees of the
Company do not receive compensation for their services as
members of the Board of Directors. Therefore, there is no
director compensation to report for Messrs. Gampp, Hable
and Malis during the fiscal year ended July 31, 2010.
2010 Director
Compensation Table
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned
|
|
|
|
|
|
|
|
|
or Paid in
|
|
Stock
|
|
Option
|
|
|
Name
|
|
Cash ($)
|
|
Awards ($)
|
|
Awards(1)
|
|
Total ($)
|
|
Lawrence C. Cardinale
|
|
$
|
32,250
|
|
|
|
|
|
|
$
|
10,890
|
|
|
$
|
43,140
|
|
Robert H. Dick
|
|
$
|
96,000
|
|
|
|
|
|
|
$
|
10,890
|
|
|
$
|
106,890
|
|
Guy R. Guarch
|
|
$
|
30,750
|
|
|
|
|
|
|
$
|
10,890
|
|
|
$
|
41,640
|
|
Juanita H. Hinshaw
|
|
$
|
31,750
|
|
|
|
|
|
|
$
|
10,890
|
|
|
$
|
42,640
|
|
|
|
|
(1) |
|
Represents the aggregate grant date fair value for all
restricted stock or stock options, as applicable, made to the
directors with respect to the fiscal year indicated, computed in
accordance with Financial Accounting Standards Board
(FASB) Accounting Standards Codification Topic 718,
Compensation Stock Compensation (formerly FASB
Statement 123R). For information about the assumptions made in
these valuation, refer to Note 13
Stock-Based Compensation Plans to the Companys
Consolidated Financial Statements included in the Companys
Annual Report on
Form 10-K
for the fiscal year ended July 31, 2010. |
|
(2) |
|
At July 31, 2010, the directors included in this table had
the following number of stock options outstanding:
Mr. Cardinale 50,000 options,
Mr. Dick 100,000 options,
Mr. Guarch 50,000 options and
Ms. Hinshaw 50,000 options. |
10
PRINCIPAL
STOCKHOLDERS
The following table sets forth as of November 5, 2010
certain information with respect to the beneficial ownership of
the Companys Common Stock by (i) each of the named
executive officers and directors, (ii) all executive
officers and directors as a group, and (iii) each person
known by the Company to beneficially own more than 5% of the
Companys Common Stock based on certain filings made under
Section 13 of the Exchange Act. All such information
provided by the stockholders who are not executive officers or
directors reflects their beneficial ownership as of the dates
specified in the relevant footnotes to the table. The percent of
shares beneficially owned is based on 24,840,441 shares
issued and outstanding as of November 5, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percent of
|
|
|
|
|
|
|
Shares
|
|
|
|
Amount and Nature of
|
|
|
Beneficially
|
|
Name and Address of Beneficial Owner
|
|
Beneficial Ownership
|
|
|
Owned
|
|
|
(i) Named Executive Officers and Directors(1)
|
|
|
|
|
|
|
|
|
David M. Hable
|
|
|
39,000
|
(2)
|
|
|
*
|
|
Lawrence C. Cardinale
|
|
|
74,244
|
(3)
|
|
|
*
|
|
Robert H. Dick
|
|
|
113,000
|
(4)
|
|
|
*
|
|
Kurt W. Gampp, Jr.
|
|
|
873,342
|
(5)
|
|
|
3.5
|
%
|
Guy R. Guarch
|
|
|
56,000
|
(6)
|
|
|
*
|
|
Juanita H. Hinshaw
|
|
|
376,710
|
(7)
|
|
|
1.5
|
%
|
Jerry L. Malis
|
|
|
1,123,245
|
(8)
|
|
|
4.5
|
%
|
Pamela G. Boone
|
|
|
183,014
|
(9)
|
|
|
*
|
|
Michael R. Fanning
|
|
|
48,275
|
(10)
|
|
|
*
|
|
Jason J. Stroisch
|
|
|
35,067
|
(11)
|
|
|
*
|
|
(ii) All Executive Officers and Directors as a Group
(8 persons)
|
|
|
2,921,897
|
(12)
|
|
|
11.6
|
%
|
(iii) Certain Beneficial Owners
|
|
|
|
|
|
|
|
|
BC Advisors, LLC, SRB Management, L.P., Steven R. Becker and
Matthew A. Drapkin
|
|
|
1,465,426
|
(13)
|
|
|
5.9
|
%
|
Louis Uchitel
|
|
|
1,593,619
|
(14)
|
|
|
6.4
|
%
|
|
|
|
* |
|
Less than 1%. |
|
(1) |
|
Except as indicated in the footnotes to this table, the persons
named in the table have sole voting and investment power with
respect to all shares of Common Stock shown as beneficially
owned by them. |
|
(2) |
|
Represents 39,000 shares issuable to Mr. Hable subject
to options exercisable currently or within 60 days of
November 5, 2010. |
|
(3) |
|
Includes 24,244 shares owned by Mr. Cardinale and
50,000 shares issuable to Mr. Cardinale subject to
options exercisable currently or within 60 days of
November 5, 2010. |
|
(4) |
|
Includes 13,000 shares owned by Mr. Dick and
100,000 shares issuable to Mr. Dick subject to options
exercisable currently or within 60 days of November 5,
2010. |
|
(5) |
|
Represents 869,842 shares held in the Kurt W. Gampp, Jr.
Trust and 3,500 shares issuable to Mr. Gampp subject
to options exercisable currently or within 60 days of
November 5, 2010. This does not include 138,725 shares
held by Julie Gampp, which transfer upon death to
Mr. Gampp, nor 62 shares held by his daughter, Lindsey
Gampp. Mr. Gampp disclaims beneficial ownership as to these
shares. |
|
(6) |
|
Includes 6,000 shares owned by Mr. Guarch and
50,000 shares issuable to Mr. Guarch subject to
options exercisable currently or within 60 days of
November 5, 2010. |
|
(7) |
|
Includes 326,710 shares held in the Hinshaw-Harrison Joint
Revocable Living Trust. Ms. Hinshaw, in her capacity as
trustee, possesses joint voting and investment power with
respect to these shares. Also includes 50,000 shares
issuable to Ms. Hinshaw subject to options exercisable
currently or within 60 days of November 5, 2010. |
11
|
|
|
(8) |
|
Includes 914,745 owned by Dr. Malis, 200,000 shares
held in the Malis Family L.P., and 8,500 shares issuable to
Dr. Malis subject to options exercisable currently or
within 60 days of November 5, 2010. The Malis Family
L.P. is a limited partnership in which Jerry L. Malis is the
general partner and possesses voting and investment power. |
|
(9) |
|
Includes the following: 70,000 shares jointly owned by
Ms. Boone and her spouse, 68,204 shares issued to
Ms. Boone subject to restrictions, including a cliff
vesting period of five years from the respective dates of the
grants and 44,810 shares issuable to Ms. Boone subject
to options exercisable currently or within 60 days of
November 5, 2010. |
|
(10) |
|
Includes the following: 7,900 shares owned solely and
1,750 shares owned jointly by Mr. Fanning and his
spouse and 38,625 shares issued to Mr. Fanning subject
to restrictions, including a cliff vesting period of five years
from the respective dates of the grants. |
|
(11) |
|
Includes the following: 400 shares owned by
Mr. Stroisch and 34,667 shares issued to
Mr. Stroisch subject to restrictions, including a cliff
vesting period of five years from the respective dates of the
grants. |
|
(12) |
|
Includes 345,810 shares issuable to named executive
officers and directors subject to options exercisable currently
or within 60 days of November 5, 2010. |
|
(13) |
|
Pursuant to Amendment No. 2 to Schedule 13G filed with
the SEC on February 16, 2010, BC Advisors, LLC (BC
Advisors), SRB Management, L.P. (SRB) and
Matthew A. Drapkin each has shared voting and dispositive power
over 1,446,326 shares, and Steven R. Becker has sole voting
and dispositive power over 19,100 shares and shared voting
and dispositive power over 1,446,326 shares. The address
for each of BC Advisors, SRB and Messrs. Drapkin and Becker
is 300 Crescent Court, Suite 1111, Dallas, Texas 75201. |
|
(14) |
|
Pursuant to Mr. Uchitels Schedule 13D/A filed
with the SEC on April 14, 2009, Mr. Uchitel has sole
voting power over 192,221 shares, shared voting power over
538,100 shares, sole dispositive power over
192,221 shares and shared dispositive power over
1,361,398 shares. Mr. Uchitels address is 142
Cedar Road, Elkins Park, Pennsylvania 19027. |
SECTION 16(a)
BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Exchange Act requires the
Companys directors and executive officers, and persons who
own more than 10% of a registered class of the Companys
equity securities, to file reports of ownership of, and
transactions in, the Companys securities with the SEC and
Nasdaq. Such directors, executive officers and 10% stockholders
are also required to furnish the Company with copies of all
Section 16(a) forms they file.
Based solely upon a review of reports furnished to the Company,
and on written representations from certain reporting persons,
the Company believes that, with respect to the fiscal year ended
July 31, 2010, each director, executive officer and 10%
stockholder of the Companys securities made timely filings
of all reports required by Section 16 of the Exchange Act
with the exception of Ms. Boone, who filed a late
Form 4 on October 19, 2010 reporting one transaction,
a restricted stock grant.
12
EXECUTIVE
COMPENSATION
2010
Summary Compensation Table
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Option
|
|
|
All Other
|
|
|
|
|
Name and Principal Position
|
|
Year
|
|
|
Salary
|
|
|
Bonus
|
|
|
Awards(1)
|
|
|
Awards(1)
|
|
|
Compensation
|
|
|
Total
|
|
|
David M. Hable(2)
|
|
|
2010
|
|
|
$
|
360,000
|
|
|
$
|
52,600
|
(3)
|
|
|
|
|
|
$
|
38,115
|
|
|
$
|
5,086
|
|
|
$
|
455,801
|
|
President & Chief Executive Officer
|
|
|
2009
|
|
|
$
|
170,000
|
|
|
|
|
|
|
|
|
|
|
$
|
38,491
|
|
|
$
|
8,128
|
|
|
$
|
216,619
|
|
Kurt W. Gampp, Jr.
|
|
|
2010
|
|
|
$
|
370,427
|
|
|
$
|
16,011
|
(3)
|
|
|
|
|
|
$
|
19,058
|
|
|
$
|
11,882
|
|
|
$
|
417,378
|
|
Executive Vice President &
|
|
|
2009
|
|
|
$
|
363,437
|
|
|
$
|
5,000
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
368,437
|
|
Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jerry L. Malis
|
|
|
2010
|
|
|
$
|
264,380
|
|
|
$
|
17,613
|
(3)
|
|
|
|
|
|
$
|
19,058
|
|
|
|
|
|
|
$
|
301,051
|
|
Executive Vice President &
|
|
|
2009
|
|
|
$
|
252,252
|
|
|
$
|
5,000
|
(3)
|
|
|
|
|
|
$
|
3,614
|
|
|
|
|
|
|
$
|
260,866
|
|
Chief Scientific Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pamela G. Boone
|
|
|
2010
|
|
|
$
|
254,703
|
|
|
$
|
9,860
|
(3)
|
|
$
|
48,640
|
|
|
$
|
19,058
|
|
|
$
|
16,960
|
|
|
$
|
349,221
|
|
Executive Vice President & Chief
|
|
|
2009
|
|
|
$
|
243,600
|
|
|
$
|
5,000
|
(3)
|
|
$
|
46,400
|
|
|
|
|
|
|
|
|
|
|
$
|
295,000
|
|
Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael R. Fanning
|
|
|
2010
|
|
|
$
|
190,000
|
|
|
$
|
20,500
|
(3)
|
|
$
|
35,339
|
|
|
|
|
|
|
$
|
8,400
|
|
|
$
|
254,239
|
|
Vice President of Domestic Sales
|
|
|
2009
|
|
|
$
|
206,375
|
|
|
$
|
18,500
|
(3)
|
|
$
|
21,789
|
|
|
|
|
|
|
$
|
8,025
|
|
|
$
|
254.689
|
|
Jason J. Stroisch
|
|
|
2010
|
|
|
$
|
190,000
|
|
|
$
|
38,500
|
(3)
|
|
$
|
38,000
|
|
|
|
|
|
|
$
|
1,327
|
|
|
$
|
267,827
|
|
Vice President of International
|
|
|
2009
|
|
|
$
|
190,000
|
|
|
$
|
38,500
|
(3)
|
|
$
|
17,561
|
|
|
|
|
|
|
$
|
1,327
|
|
|
$
|
247,388
|
|
Sales & Marketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Represents the aggregate grant date fair value for all
restricted stock or stock options, as applicable, made to the
named executive officers with respect to the fiscal year
indicated, computed in accordance with FASB Accounting Standards
Codification Topic 718, Compensation Stock
Compensation (formerly FASB Statement 123R). For information
about the assumptions made in these valuation, refer to
Note 13 Stock-Based Compensation
Plans to the Companys Consolidated Financial
Statements included in the Companys Annual Report on
Form 10-K
for the fiscal year ended July 31, 2010. |
|
(2) |
|
Mr. Hable was appointed the Companys President, Chief
Executive Officer and director on January 29, 2009. |
|
(3) |
|
Includes Christmas bonus of $5,000 for each of Mr. Hable,
Mr. Gampp, Dr. Malis and Ms. Boone plus an amount
based upon their percentage of objectives achieved in the
Company-wide objectives and the functional and personal
development objectives. Includes Christmas bonus of $500 for
each of Mr. Fanning and Mr. Stroisch plus an amount
based upon their percentage of objectives achieved in the
Company-wide objectives and functional and personal development
objectives. |
Narrative
to Summary Compensation Table
During the 2008 fiscal year, the terms of employment for
Messrs. Gampp and Malis were governed by each of their
employment agreements with the Company entered into in 2005.
During the 2008 and 2009 fiscal years, the terms of employment
for Ms. Boone were governed by her employment agreement
with the Company entered into in 2007. Pursuant to the terms of
their agreements, Mr. Gampps initial base salary was
$346,000, Dr. Malis initial base salary was $230,000,
and Ms. Boones initial base salary was $232,000;
provided that after the first year of employment, each of their
base salaries was determined by the Compensation Committee,
subject to Board approval, and in no event could be lower than
their respective initial base salaries. In addition, each of
them received such other benefits that the Company provides to
its executive officers, including healthcare, life insurance,
disability and 30 days of paid vacation. Each of
Messrs. Gampp and Malis and Ms. Boone was eligible to
receive an annual bonus as determined in the sole discretion of
the Compensation Committee. Messrs. Gampps and
Malis employment agreements expired on September 21,
2008 according to their terms, and Ms. Boones
employment agreement expired on July 31, 2010 according to
its terms.
Messrs. Hable, Gampp and Malis and Ms. Boone have
entered into change in control agreements, the terms of which
are more fully discussed in the section EMPLOYMENT
AGREEMENTS AND SEVERANCE AGREEMENTS below.
13
2010
Outstanding Equity Awards at Fiscal Year-End
The following table sets forth information on outstanding
options and stock awards held by the named executive officers as
of July 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity Incentive
|
|
|
Plan Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan Awards:
|
|
|
Market or
|
|
|
|
Number of
|
|
|
Number of
|
|
|
|
|
|
|
|
|
Number of
|
|
|
Payout Value of
|
|
|
|
Securities
|
|
|
Securities
|
|
|
|
|
|
|
|
|
Unearned
|
|
|
Unearned
|
|
|
|
Underlying
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
Shares, Units or
|
|
|
Shares, Units or
|
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Option
|
|
|
Option
|
|
|
Other Rights
|
|
|
Other Rights
|
|
|
|
Options (#)
|
|
|
Options (#)
|
|
|
Exercise
|
|
|
Expiration
|
|
|
That Have Not
|
|
|
That Have Not
|
|
Name
|
|
Exercisable
|
|
|
Unexercisable
|
|
|
Price ($)
|
|
|
Date
|
|
|
Vested (#)
|
|
|
Vested ($)
|
|
|
David M. Hable
|
|
|
28,000
|
(1)
|
|
|
20,000
|
(1)
|
|
$
|
1.00
|
|
|
|
1/19/18
|
|
|
|
|
|
|
|
|
|
|
|
|
4,083
|
(2)
|
|
|
30,917
|
(2)
|
|
$
|
1.37
|
|
|
|
12/18/19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jerry L. Malis
|
|
|
5,000
|
(3)
|
|
|
|
|
|
$
|
0.90
|
|
|
|
12/12/18
|
|
|
|
|
|
|
|
|
|
|
|
|
2,042
|
(4)
|
|
|
15,458
|
(4)
|
|
$
|
1.37
|
|
|
|
12/18/19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kurt W. Gampp, Jr.
|
|
|
2,042
|
(4)
|
|
|
15,458
|
(4)
|
|
$
|
1.37
|
|
|
|
12/18/19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pamela G. Boone
|
|
|
41,310
|
(5)
|
|
|
|
|
|
$
|
1.089
|
|
|
|
5/19/15
|
|
|
|
|
|
|
|
|
|
|
|
|
2,042
|
(4)
|
|
|
15,458
|
(4)
|
|
$
|
1.37
|
|
|
|
12/18/19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,387
|
(6)
|
|
$
|
35,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,050
|
(7)
|
|
$
|
40,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,263
|
(8)
|
|
$
|
46,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35,504
|
(9)
|
|
$
|
48,640
|
|
Michael R. Fanning
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,714
|
(6)
|
|
$
|
20,353
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,949
|
(7)
|
|
$
|
7,055
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,167
|
(8)
|
|
$
|
21,789
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,795
|
(9)
|
|
$
|
35,339
|
|
Jason J. Stroisch
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,153
|
(7)
|
|
$
|
4,174
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,777
|
(8)
|
|
$
|
17,561
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27,737
|
(9)
|
|
$
|
38,000
|
|
|
|
|
(1) |
|
Represents an option to purchase 48,000 shares of Common
Stock granted on January 29, 2009. One twelfth of this
option vested on January 29, 2009 and the remainder vests
proratably over the next 11 quarters. |
|
(2) |
|
Represents an option to purchase 35,000 shares of Common
Stock granted on December 18, 2009 and the remainder vests
proratably over the next 60 months. |
|
(3) |
|
Represents an option to purchase 5,000 shares of Common
Stock which vests proratably at the end of each quarter over a
twelve month period beginning on December 12, 2008. |
|
(4) |
|
Represents options to purchase 17,500 shares of Common
Stock granted on December 18, 2009 and the remainder vests
proratably over the next 60 months. |
|
(5) |
|
Represents an option to purchase 41,310 shares of Common
Stock. |
|
(6) |
|
These shares vest on March 7, 2011. |
|
(7) |
|
These shares vest on August 1, 2012. |
|
(8) |
|
These shares vest on August 1, 2013. |
|
(9) |
|
These shares vest on August 1, 2014. |
EMPLOYMENT
AGREEMENTS AND SEVERANCE AGREEMENTS
Mr. Hable and the Company entered into a change in control
agreement, effective as of January 29, 2009. In addition,
on December 9, 2009, the Company entered into change of
control agreements with Messrs. Gampp and Malis effective
August 1, 2009, and with Ms. Boone on October 12,
2010, effective August 1, 2010. The change in
14
control agreements have rolling one-year terms and expire
30 days after the executives employment is
terminated. Payments to which the executive is due under the
change in control agreement are not subject to reduction in the
event he or she receives other compensation for services
rendered after termination of employment, and the executive is
under no duty to mitigate any payments.
The change in control agreements provide that if the
executives employment is terminated within one year
following a change in control for cause or disability (as both
are defined in the change in control agreement), as a result of
his or her death or by the executive other than as Involuntary
Termination (as defined in the change in control agreement), the
Company shall pay to the executive all compensation earned or
accrued through the employment termination date, including
(i) base salary; (ii) reimbursement for reasonable and
necessary expenses; (iii) vacation pay; (iv) bonuses
and incentive compensation; and (v) all other amounts to
which he or she is entitled under any compensation or benefit
plan of the Company (Standard Compensation Due).
If Mr. Hables employment is terminated within one
year following a change in control without cause and for any
reason other than death or disability, including involuntary
termination, and provided he enters into a separation agreement
within 30 days of his employment termination, he shall
receive the following in a lump sum (early
severance): (i) all Standard Compensation Due;
(ii) an amount equal to one-half times his annual base
salary at the rate in effect immediately prior to the change in
control; and (iii) as compensation for certain lost
benefits, an amount equal to 10% of his base salary at the rate
in effect immediately prior to the change in control. If such
termination occurs during the period that is 6 to 12 months
after Mr. Hables start date (as defined in the change
in control agreement), he shall receive in a lump sum the early
severance and an additional amount equal to the sum of
one-twelfth times his base salary for each month of employment
completed between 7 and 12 months after his start date. If
Mr. Hable is terminated at any time after the first
anniversary of his start date, he shall receive the following
(ordinary severance): (i) all Standard
Compensation Due; (ii) an amount equal to one times his
annual base salary at the rate in effect immediately prior to
the change in control; and (iii) any amount payable as of
the termination date under the Companys objectives-based
incentive plan. Such ordinary severance shall be paid in 12
equal monthly installments beginning in the month following
Mr. Hables employment termination. Furthermore, all
of Mr. Hables awards of shares or options shall
immediately vest and be exercisable for one year after the date
of his involuntary employment termination.
If Messrs. Gampp or Malis or Ms. Boone is terminated
within one year following a change in control without cause and
for any reason other than death or disability, including
involuntary termination, and provided the executive enters into
a separation agreement within 30 days of the employment
termination, the executive shall receive an amount equal to the
sum of the following: (i) all Standard Compensation Due;
(ii) an amount equal to one times the annual base salary at
the rate in effect immediately prior to the change in control;
and (iii) any amount payable as of the termination date
under the Companys objectives-based incentive plan. Such
amount shall be paid in 12 equal monthly installments beginning
in the month after such termination. Furthermore, all awards of
shares or options shall immediately vest and be exercisable for
one year after the date of involuntary employment termination.
As defined in the change in control agreement, a change in
control means: (i) the acquisition by any person (as
defined in the change in control agreement) of securities of the
Company representing 51% or more of the combined voting power of
the Companys outstanding voting securities; (ii) a
change in the composition of the Board of Directors of the
Company such that during any period of up to two consecutive
years, individuals who constitute members of the Board of
Directors at the beginning of the period cease to constitute the
majority thereof; and (iii) the closing of certain mergers
or consolidations of the Company with any other corporation.
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Since the late 1960s, the late Dr. Leonard Malis, one
of Valley Forges former directors, on an individual basis
has been a party to consulting and other agreements with
Codman & Shurtleff, Inc., the Companys principal
customer. Since 1983, Dr. Leonard Malis has been a party to
an agreement with Codman under which Dr. Leonard Malis
received royalty payments for the use of the
Malis®
trademark on certain products sold by Codman to end users,
including products Valley Forge sold to Codman. Dr. Leonard
Malis developed neurosurgical instruments for Codman with no
pecuniary benefits to Valley Forge. On October 22, 2004,
Valley Forge entered into an option
15
agreement with Dr. Leonard Malis under which Valley Forge
was granted an option to acquire the
Malis®
trademark from Dr. Leonard Malis at any time over a period
of five years.
On October 12, 2005, the Company exercised its option with
respect to the
Malis®
trademark. The Company paid the estate of Dr. Leonard I.
Malis $159,904 in cash and the remainder in a $3,997,600
promissory note which will be paid in 25 equal quarterly
installments of $159,904. The Company made four quarterly
payments on this note during each of the years ended
July 31, 2010 and 2009. The outstanding balance as of
July 31, 2010 was approximately $911,000. In addition, the
Company has made one quarterly payment and intends to make three
additional quarterly payments during the fiscal year ending
July 31, 2011. The promissory note is secured by a security
interest in the trademark and our
DualWavetm
patents.
PROPOSAL 2
RATIFICATION OF THE APPOINTMENT OF THE COMPANYS
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The firm of UHY LLP (UHY) acts as our independent
registered public accounting firm. UHY LLP personnel work under
the direct control of UHY LLP partners and are leased from
wholly-owned subsidiaries of UHY Advisors, Inc. in an
alternative practice structure.
The following table shows fees billed for professional services
rendered by UHY for fiscal 2010 and fiscal 2009:
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year Ended
|
|
Fiscal Year Ended
|
|
|
July 31, 2010
|
|
July 31, 2009
|
|
Audit Fees(1)
|
|
$
|
270,628
|
|
|
$
|
251,188
|
|
Audit-Related Fees(2)
|
|
$
|
10,035
|
|
|
|
9,629
|
|
Tax Fees(3)
|
|
$
|
|
|
|
|
3,618
|
|
Total
|
|
$
|
280,663
|
|
|
$
|
264,435
|
|
|
|
|
(1) |
|
Audit Fees for the fiscal years ended July 31, 2010 and
2009 represent fees for services for the audit of the
consolidated financial statements, the review of the quarterly
financial statements and consultation concerning financial
accounting and reporting standards. |
|
(2) |
|
Audit-Related Fees for the fiscal years ended July 31, 2010
and 2009 represent fees for services for the audit of the
Synergetics, Inc. Incentive Savings Plan. |
|
(3) |
|
Tax Fees are comprised of fees relating to the preparation of
Form 5500. |
Pursuant to the Audit Committees charter, all audit and
permissible non-audit services provided by the independent
registered public accounting firm must be pre-approved. These
services may include audit services, audit-related services, tax
services and other services. Pre-approval is generally provided
for up to one year and any pre-approval is detailed as to the
particular service or category of service. The independent
registered public accounting firm and management are required to
periodically report to the Audit Committee regarding the extent
of services provided by the independent registered public
accounting firm in accordance with the policies set forth in the
Audit Committee charter. Consistent with the Audit
Committees policy, all audit and permissible non-audit
services provided by UHY during the fiscal years ended
July 31, 2010 and 2009 were pre-approved by the Audit
Committee.
In considering the nature of the services provided by the
independent registered public accounting firm for the fiscal
year ended July 31, 2010, the Audit Committee determined
that such services are compatible with the provision of
independent audit services. The Audit Committee discussed these
services with the independent registered public accounting firm
and management for the fiscal year ended July 31, 2010 to
determine that they are permitted under the rules and
regulations concerning auditors independence promulgated
by the SEC to implement the Sarbanes-Oxley Act of 2002, as well
as rules of the American Institute of Certified Public
Accountants.
UHY acted as the Companys independent registered public
accounting firm for the 2010 fiscal year. The Audit Committee
selected UHY to act as the Companys independent registered
public accounting firm for the 2011 fiscal
16
year. UHY representatives are expected to attend the Annual
Meeting. They will have an opportunity to make a statement if
they desire to do so and will be available to respond to
appropriate questions.
The Company is asking its stockholders to ratify the selection
of UHY as the Companys independent registered public
accounting firm. Although ratification is not required by our
bylaws or otherwise, the Board is submitting the selection of
UHY to our stockholders for ratification as a matter of good
corporate practice. If the selection is not ratified, the Audit
Committee will consider whether it is appropriate to select
another independent registered public accounting firm. Even if
the selection is ratified, the Audit Committee in its discretion
may select a different independent registered public accounting
firm at any time during the fiscal year if it determines that
such a change would be in the best interests of the Company and
its stockholders.
THE BOARD
OF DIRECTORS RECOMMENDS A VOTE FOR RATIFICATION OF THE
APPOINTMENT OF THE COMPANYS INDEPENDENT REGISTERED
PUBLIC
ACCOUNTING FIRM
REPORT OF
THE AUDIT COMMITTEE
The Audit Committee (the Committee) oversees the
Companys financial reporting process on behalf of the
Board of Directors. Management has the primary responsibility
for the financial statements and the reporting process,
including internal control systems. The Companys
independent registered public accounting firm is responsible for
expressing an opinion on the conformity of the Companys
audited financial statements with U.S. generally accepted
accounting principles.
In fulfilling its oversight responsibilities, the Committee
reviewed and discussed with management the audited financial
statements in the Annual Report on
Form 10-K
for the fiscal year ended July 31, 2010, including a
discussion of the accounting principles, the reasonableness of
significant judgments and the clarity of disclosures in the
financial statements.
In addition, the Committee discussed with the independent
registered public accounting firm the matters required to be
discussed by the Statement on Auditing Standards No. 61, as
amended, as adopted by the Public Company Accounting Oversight
Board in Rule 3200T. The Committee met with the independent
registered public accounting firm, with and without management
present, to discuss the results of their examinations and the
overall quality of the Companys financial reporting. In
addition, the Audit Committee has reviewed and discussed with
management and UHY LLP managements report on internal
control over financial reporting in accordance with
Section 404 of the Sarbanes-Oxley Act of 2002.
The Committee has received the written disclosures and the
letter from the independent registered public accounting firm
required by applicable requirements of the Public Company
Accounting Oversight Board regarding the independent registered
public accounting firms communications with the Committee
concerning independence, and has discussed with the independent
registered public accounting firm the independent registered
public accounting firms independence.
In reliance on the reviews and discussions referred to above,
the Committee recommended to the Board of Directors (and the
Board has approved) that the audited financial statements be
included in the Annual Report on
Form 10-K
for the fiscal year ended July 31, 2010, filed with the SEC.
Submitted by the Audit Committee of the Board of Directors.
Juanita H. Hinshaw (Chairperson)
Lawrence C. Cardinale
Robert H. Dick
17
OTHER
MATTERS
Management does not know of any other business that may be
considered at the Annual Meeting. However, if any matters other
than those referred to above should properly come before the
Annual Meeting, it is the intention of the persons named in the
accompanying form of proxy to vote the proxies held by them in
accordance with their best judgment.
The Company will bear the costs of its solicitation of proxies.
In addition to the use of the mails, proxies may be solicited by
electronic mail, personal interview, telephone, telegram and
telefax by the directors, officers and employees of the Company.
Arrangements will also be made with brokerage houses and other
custodians, nominees and fiduciaries for the forwarding of
solicitation material to the beneficial owners of stock held of
record by such persons, and the Company may reimburse such
custodians, nominees and fiduciaries for reasonable
out-of-pocket
expenses incurred by them in connection therewith.
ANNUAL
REPORT ON
FORM 10-K
Along with mailing the proxy materials, we have included a copy
of our Annual Report on
Form 10-K
for the fiscal year ended July 31, 2010. We will provide
stockholders with additional copies of our Annual Report on
Form 10-K
for the fiscal year ended July 31, 2010, without charge,
upon written request to Pamela G. Boone, Secretary, Synergetics
USA, Inc., 3845 Corporate Centre Drive, OFallon, Missouri
63368.
HOUSEHOLDING
OF PROXY MATERIALS
The SEC has adopted rules that permit companies and
intermediaries (e.g. brokers) to satisfy the delivery
requirements for proxy statements and annual reports with
respect to two or more stockholders sharing the same address by
delivering a single proxy statement and annual report addressed
to those stockholders. This process, which is commonly referred
to as householding, potentially means extra
convenience for stockholders and cost savings for companies.
A number of brokers with accountholders who are stockholders
will be householding our proxy materials. As indicated in the
notice previously provided by these brokers to stockholders, a
single proxy statement and annual report will be delivered to
multiple stockholders sharing an address unless contrary
instructions have been received from an affected stockholder.
Once you have received notice from your broker or us that they
will be householding communications to your address,
householding will continue until you are notified otherwise.
Stockholders who currently receive multiple copies of the proxy
materials at their address and would like to request
householding of their communications should contact their broker
or, if a stockholder is a direct holder of shares of our Common
Stock, they should submit a written request to our transfer
agent, American Stock Transfer & Trust Company,
6201 15th Avenue, Brooklyn, New York 11219.
To delist yourself from householding in the future you may write
the Company at 3845 Corporate Centre Drive, OFallon,
Missouri 63368, Attention: Pamela G. Boone or call
(636) 939-5100.
Upon written or oral request directed to the Company at the
address or phone number listed above, we will deliver promptly a
separate copy of the proxy materials.
STOCKHOLDER
PROPOSALS FOR 2011 ANNUAL MEETING OF STOCKHOLDERS
Stockholder proposals submitted for inclusion in the proxy
statement and form of proxy for the 2011 Annual Meeting of
Stockholders must be received at the corporate offices of the
Company, addressed to the attention of Ms. Pamela G. Boone,
Secretary, Synergetics USA, Inc. no later than July 15,
2011. The proposals must comply with the rules of the SEC
relating to stockholder proposals. The Companys Bylaws
provide that no business may be brought before an annual meeting
unless specified in the notice of meeting, brought before the
meeting by or at the direction of the Board of Directors, or
otherwise brought by a stockholder who has delivered notice to
the Company (containing certain information specified in the
Bylaws) not less than 60 or more than 90 days before the
18
anniversary date of the immediately preceding annual meeting of
stockholders. Therefore, for the 2010 Annual Meeting of
Stockholders, such notice must be delivered no earlier than
September 17, 2011 and no later than October 17, 2011.
A copy of the full text of these Bylaw provisions may be
obtained by writing to the Secretary at the address indicated
above.
By Order of the Board of Directors,
PAMELA G. BOONE
Secretary
November 12, 2010
19
ANNUAL MEETING OF STOCKHOLDERS OF
SYNERGETICS USA, INC.
December 16, 2010
NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL:
The Notice of Meeting, proxy statement and proxy card
are available at http://www.amstock.com/ProxyServices/ViewMaterial.asp?CoNumber=06536
Please sign, date and mail
your proxy card in the
envelope provided as soon
as possible.
â Please detach along perforated line and mail in the envelope provided. â
n 20230000000000001000 9
121610
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Board of Directors recommends a vote FOR all director nominees and Proposal 2.
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE
ý
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FOR
|
|
AGAINST
|
|
ABSTAIN |
1.
|
|
Election of Directors: |
|
|
2. |
|
Ratification of the appointment of UHY LLP as
independent registered public accounting firm |
|
o |
|
o |
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NOMINEES: |
|
|
|
|
|
|
|
|
|
|
|
|
o
|
|
FOR ALL NOMINEES
|
|
¡ |
|
Lawrence C. Cardinale |
|
|
|
|
This proxy, when properly executed, will be voted in the manner
directed herein by the undersigned stockholder. IF NO DIRECTION IS
MADE, THIS PROXY WILL BE VOTED FOR ALL PROPOSALS.
PLEASE SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED
ENVELOPE EVEN IF YOU PLAN TO ATTEND THE MEETING.
|
|
|
¡ |
|
Guy R. Guarch
|
|
|
|
|
o o
|
|
WITHHOLD AUTHORITY FOR ALL NOMINEES
FOR ALL EXCEPT (See instructions below)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INSTRUCTIONS: To withhold authority to vote for any individual nominee(s),
mark FOR ALL EXCEPT and fill in the circle next to
each nominee you wish to
withhold, as shown here: = |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MARK X HERE IF YOU PLAN TO ATTEND THE MEETING. o |
|
|
|
To change the address on your account, please check the box
at right and indicate your new address in the address space
above. Please note that changes to the registered name(s)
on the account may not be submitted
via this method. |
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature
of Stockholder
|
|
Date:
|
|
|
|
Signature
of Stockholder
|
|
Date:
|
|
|
|
|
|
Note: |
|
Please sign exactly as your name or names appear on this Proxy. When shares are held jointly,
each holder should sign. When signing as executor, administrator, attorney, trustee or guardian,
please give full title as such. If the signer is a corporation, please sign full corporate name by
duly authorized officer, giving full title as such. If signer is a partnership, please sign in
partnership name by authorized person. |
|
n
n
o
n
SYNERGETICS USA, INC.
PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF
SYNERGETICS USA, INC.
FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 16, 2010
The undersigned, having received the notice and accompanying Proxy Statement for said meeting,
hereby appoints Pamela G. Boone and Peter T. Rasche, and each of them, with full power of
substitution, as the undersigneds proxies and attorneys-in-fact to vote at the Annual Meeting of
Stockholders of Synergetics USA, Inc. (the Company) to be held on December 16, 2010 (the Annual
Meeting), or at any adjournment thereof, all shares of voting stock of the Company which the
undersigned may be entitled to vote. The above proxies are hereby instructed to vote as shown on
the reverse of this card and in their discretion upon such other business as may properly come
before the Annual Meeting or at any adjournment or postponement thereof.
(Continued and to be signed on the reverse side.)
n
14475 n